Cycle 1–3 (1 cycle = 2 weeks)
|
- Rituximab 500 mg/m2 i.v.*
|
x
| | | | | | |
- MTX 3000–5000 mg/m2 i.v.
| |
x
| | | | | |
- Ifosfamide 800 mg/m2 i.v.
| | |
x
|
x
|
x
| | |
- Liposomal AraC 50 mg i.th.**
| | |
x
| | | | |
Cycle 4 + 6 (1 cycle = 3 weeks)
|
- Cytarabine 3000 mg/m2 i.v
| |
x
|
x
| | | | |
- Liposomal AraC 50 mg i.th.**
| | | |
x
| | | |
- MTX 2,5 mg + prednisolone 3 mg intraventricular (patients < 65 ys)*
| | | |
x
|
x
|
x
| |
- AraC 10 mg intraventricular (patients < 65 ys)*
| | | | | | |
x
|
Cycle 5 (1 cycle = 2 weeks)
|
- MTX 3000–5000 mg/m2 i.v.
| |
x
| | | | | |
- Ifosfamide i.v. 800 mg/m2 i.v.
| | |
x
|
x
|
x
| |
- Liposomal AraC 50 mg i.th.**
| | |
x
| | | |
- MTX 2,5 mg + prednisolone 3 mg intraventricular (patients < 65 ys)*
| | |
x
|
x
|
x
| |
- AraC10 mg intraventricular (patients < 65 ys)*
| | | | | |
x
|
Cycle 5 was repeated for patients < 65 ys
| | | | | | |